Recevez les dernières nouvelles sur l'action Sandoz Group avec des mises à jour sur les tendances du marché, les données financières et les analyses de Benzinga. Restez informé des performances de SDZXF

Dernières nouvelles pour

Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in its pipeline.

Comments

Sandoz Group Actualités boursières

Actualités

Dernières nouvelles pour

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL